Product ID: SQSG35I2003
Report ID:
SQSG35I2003 |
Region:
Global |
Published Date: April, 2024
Pages:
242
|
Tables:
115 |
Figures:
69
Rheumatoid Arthritis Drugs Market Driver
Increasing Efficacy of Medications in the Treatment of Rheumatoid Arthritis, Combined with Favorable Reimbursement Policies
Global rheumatoid arthritis drugs market is projected to grow at a CAGR of 2.75% from 2022 to 2028, owing to increasing efficacy of medications in the treatment of RA and favorable reimbursement policies. The market for biologics is expected to grow at a higher rate, owing to the advent of novel therapies and increasing awareness about the disease. Currently, there are two types of rheumatoid arthritis drugs available in the market, namely monoclonal antibodies (MoA) and non-biologic agents. MoA drugs are more expensive than non-biologic agents, but have a higher efficacy rate. Non-biologic agents are cheaper than MoA drugs, but their efficacy rate is lower. The growing geriatric population is expected to drive the growth of the rheumatoid arthritis drugs market during the forecast period. Wherein, the biologics category is expected to hold the highest market share.
Rheumatoid Arthritis Drugs Market Restraint
High Treatment Cost
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONRheumatoid Arthritis Drugs Market size was valued at USD 59.031 billion in 2019 and is poised to grow from USD 60.02 billion in 2023 to USD 70 billion by 2031, growing at a CAGR of 1.72% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQSG35I2003